Deciphera’s $400M follow-on adds firepower on strength of GIST readout

Deciphera’s offering shows investor demand is strong for companies with late-stage success stories

Outsized investor demand continues unabated for stocks of companies with late stage clinical success stories, as evidenced by Deciphera’s ability to double the size of its follow-on to $400 million with little to no haircut despite turbulent macroeconomic headwinds.

On the strength of a gastrointestinal cancer readout that led to an 80% gain

Read the full 520 word article

How to gain access

Continue reading with a
two-week free trial.